Moderna products by NPV worldwide 2021 | Statista

Try our business solution for free!

As of August 2021, the net present value of Moderna's COVID-19 vaccine, Spikevax, was around 20.2 billion U.S. dollars. This statistic illustrates the net present value (NPV) of Moderna products worldwide as of August 2021, in million U.S. dollars.

Net Present Value (NPV) of Moderna products worldwide as of August 2021 (in million U.S. dollars)

Product (therapy area, development phase)	NPV in million U.S. dollars
Spikevax (COVID-19 vaccine, marketed)	20,199
mRNA-1647 (Cytomegalovirus vaccine, phase 2)	2,484
mRNA-1345 (RSV vaccine, phase 1)	2,002
mRNA-2752 (solid tumors/lymphoma, phase 1)	775
mRNA-1653 (hMPV/PIV3 vaccine, phase 1)	529
AXD8601 (Myocardial ischaemia therapy, phase 2)	282
mRNA-3927 (Propionic acidaemia therapy, phase 1)	276
mRNA-1893 (Zika vaccine, phase 1)	252
mRNA-3283 (Phenylketonuria therapy, preclinical)	208
mRNA-4157 (Personalised cancer vaccine, phase 2)	97
mRNA-1944 (Chikungunya anti-viral, phase 1)	5
mRNA-5671 (Kras vaccine, phase 1)	1

Loading statistic...

Download

Source

Show detailed source information?

Register for free

Already a member?

Sources

Use Ask Statista Research Service

Release date

August 2021

More information

Region

Worldwide

Survey time period

as of August 2021

Citation formats

Other statistics on the topic
mRNA technology

Revenue of Moderna Inc. from 2016 to 2022 (in million U.S. dollars)

Pharmaceutical Products & Market

Moderna's revenue 2016-2022

Forecasted sales of select COVID-19 vaccines worldwide in 2021 and 2022 (in billion U.S. dollars)

Pharmaceutical Products & Market

Forecasted sales of select COVID-19 vaccines worldwide 2021-2022

Revenue of BioNTech SE from 2017 to 2021 (in million euros)

Pharmaceutical Products & Market

Revenue of BioNTech 2017-2021

World's top 50 pharmaceutical and biotechnology companies based on R&D intensity in 2021

Pharmaceutical Products & Market

Top 50 global pharmaceutical and biotech companies by R&D intensity in 2021

Statista Accounts: Access All Statistics. Starting from $468 USD / Year

Basic Account

Get to know the platform

You only have access to basic statistics.

Starter Account

The ideal entry-level account for individual users

Instant access to 1m statistics
Download in XLS, PDF & PNG format
Detailed references

$59 USD $39 USD / Month *

in the first 12 months

Professional Account

Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " mRNA technology "

The most important statistics

The most important statistics

The most important statistics

The most important statistics

The most important statistics

The most important statistics

Statistics on mRNA technology

Overview

5

Research and development

5

COVID-19

6

Leading companies

4

Focus: Moderna

5

Focus: BioNTech

4

Further related statistics

11

Further Content: You might find this interesting as well

Statistics

Topics

mRNA technology

Biotechnology industry in Germany

Biotechnology in Europe

Coronavirus (COVID-19) vaccines and treatments

Statista Accounts: Access All Statistics. Starting from $468 USD / Year

Learn more about how Statista can support your business.